File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: TrkB as a therapeutic target for ovarian cancer

TitleTrkB as a therapeutic target for ovarian cancer
Authors
Siu, MKYWong, OGWCheung, ANY
KeywordsBDNF
Ovarian cancer
Therapeutic target
TrkB
Issue Date2009
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett
Citation
Expert Opinion On Therapeutic Targets, 2009, v. 13 n. 10, p. 1169-1178 How to Cite?
DOI: http://dx.doi.org/10.1517/14728220903196787
AbstractBackground: In many countries, ovarian cancer is the most lethal gynecological malignancy. Its poor prognosis is mainly due to the late stage of disease with metastasis at presentation. The significant failure rate of chemotherapy in patients with advanced stage disease is also a main concern. As such, developing novel therapeutic targets is essential to improve long-term survival. Overexpression of Tropomyosin-related kinase B (TrkB), a tyrosine kinase receptor, has been documented in ovarian cancer and is found to be correlated with poor prognosis. Objective/methods: We discuss the functional roles and the related downstream signaling pathways of TrkB and its ligand brain-derived neurotrophic factor (BDNF) in ovarian cancer. The possible crosstalk between TrkB/BDNF and other putative molecular targets in ovarian cancer is also discussed. Results/conclusions: All these latest findings shed light on the application of TrkB as a therapeutic target for ovarian cancer. © 2009 Informa UK Ltd All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/88605
ISSN
1472-8222
2023 Impact Factor: 4.6
2023 SCImago Journal Rankings: 1.423
ISI Accession Number ID
WOS:000271400600004
Funding AgencyGrant Number
Hong Kong Anti-Cancer Society
Funding Information:

The work described in this paper was supported by a grant from the Hong Kong Anti-Cancer Society.

References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorSiu, MKYen_HK
dc.contributor.authorWong, OGWen_HK
dc.contributor.authorCheung, ANYen_HK
dc.date.accessioned2010-09-06T09:45:34Z-
dc.date.available2010-09-06T09:45:34Z-
dc.date.issued2009en_HK
dc.identifier.citationExpert Opinion On Therapeutic Targets, 2009, v. 13 n. 10, p. 1169-1178en_HK
dc.identifier.issn1472-8222en_HK
dc.identifier.urihttp://hdl.handle.net/10722/88605-
dc.description.abstractBackground: In many countries, ovarian cancer is the most lethal gynecological malignancy. Its poor prognosis is mainly due to the late stage of disease with metastasis at presentation. The significant failure rate of chemotherapy in patients with advanced stage disease is also a main concern. As such, developing novel therapeutic targets is essential to improve long-term survival. Overexpression of Tropomyosin-related kinase B (TrkB), a tyrosine kinase receptor, has been documented in ovarian cancer and is found to be correlated with poor prognosis. Objective/methods: We discuss the functional roles and the related downstream signaling pathways of TrkB and its ligand brain-derived neurotrophic factor (BDNF) in ovarian cancer. The possible crosstalk between TrkB/BDNF and other putative molecular targets in ovarian cancer is also discussed. Results/conclusions: All these latest findings shed light on the application of TrkB as a therapeutic target for ovarian cancer. © 2009 Informa UK Ltd All rights reserved.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/etten_HK
dc.relation.ispartofExpert Opinion on Therapeutic Targetsen_HK
dc.rightsExpert Opinion On Therapeutic Targets. Copyright © Informa Healthcare.en_HK
dc.subjectBDNFen_HK
dc.subjectOvarian canceren_HK
dc.subjectTherapeutic targeten_HK
dc.subjectTrkBen_HK
dc.subject.meshAntineoplastic Agents - pharmacologyen_HK
dc.subject.meshBrain-Derived Neurotrophic Factor - antagonists & inhibitorsen_HK
dc.subject.meshCentral Nervous System Diseases - drug therapyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshNeuroblastoma - drug therapyen_HK
dc.subject.meshOvarian Neoplasms - drug therapyen_HK
dc.subject.meshReceptor, trkB - metabolismen_HK
dc.titleTrkB as a therapeutic target for ovarian canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1472-8222&volume=&spage=&epage=&date=2009&atitle=TrkB+as+a+therapeutic+target+for+ovarian+canceren_HK
dc.identifier.emailSiu, MKY: mkysiu@hkucc.hku.hken_HK
dc.identifier.emailCheung, ANY: anycheun@hkucc.hku.hken_HK
dc.identifier.authoritySiu, MKY=rp00275en_HK
dc.identifier.authorityCheung, ANY=rp00542en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14728220903196787en_HK
dc.identifier.pmid19694498-
dc.identifier.scopuseid_2-s2.0-70349398835en_HK
dc.identifier.hkuros166030en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70349398835&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume13en_HK
dc.identifier.issue10en_HK
dc.identifier.spage1169en_HK
dc.identifier.epage1178en_HK
dc.identifier.isiWOS:000271400600004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridSiu, MKY=24924018400en_HK
dc.identifier.scopusauthoridWong, OGW=7004813981en_HK
dc.identifier.scopusauthoridCheung, ANY=54927484100en_HK
dc.identifier.citeulike5789771-
dc.identifier.issnl1472-8222-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats